A multiregional, randomized, controlled, open-label, phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Trial in progress.

Authors: Lin Shen, Kohei Shitara, Qi Mei, Changzheng Li, Jia Wei, Xianhe Xie, Ping Chen, Zhihu Li, Ninggang Zhang, Yanqiao Zhang, Lili Sheng, Xiaobing Chen, Qunyi Guo, Jianwei Yang, Zhenyang Liu, Xinjun Liang, Ming Liu, Yongdong Jin, Zhimin Gong, Hui Zhou

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4201

Source: Full article

---

Abstract

TPS4201